A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Dose Escalation of GS1-144 Tablets and the Effects of Food on the Pharmacokinetics of GS1-144 in a Chinese Population

A Phase I clinical study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral dose escalation of GS1-144 tablets and the effects of food on the pharmacokinetics of GS1-144 in a Chinese population

Study Overview

• Status: Completed
• Conditions: Healthy Volunteer; Vasomotor System; Labile
• Intervention / Treatment: Drug: GS1-144 tablet

Detailed Description

The primary purpose of this study is to assess the safety and tolerability of single ascending doses of GS1-144 in healthy participants in Part 1 and assessing the food effect in Part 2,and to assess the safety and tolerability of multiple ascending doses of GS1-144 in healthy postmenopausal female participants in Part 3.

• Study Type: Interventional
• Enrollment (Actual): 110
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Shanghai
    • Shanghai, Shanghai, China, 200040
      • Huashan Hospital, Fudan University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

At the time of signing the informed consent form (ICF):

Part 1and Part 2 only: healthy male and female subjects aged between 18 and 45 years inclusive; Part 3 only: healthy women aged between 40 and 65 years inclusive who have undergone natural menopause (natural menopause is defined as surgically sterile (hysterectomy, bilateral salpingectomy, tubal ligation or bilateral oophorectomy - verbal confirmation through medical history review acceptable) or postmenopausal (no menses for 12 months and confirmed by FSH level ≥40 mlU/mL);

• Body weight ≥ 50 kg (male), ≥ 45 kg (female) with a body mass index between 19.0 and 27.9 kg/m2 inclusive at screening
• From signing the ICF to 1 month (female subjects) /3 months (male subjects and their female partners) after the end of the study, no family planning and egg/sperm donation plans, and effective contraceptive methods (such as IUD, bilateral tubal/vasectomy, condom and safe period calculation, etc.) (applicable to Parts 1 and 2)' ' ● Volunteer to sign ICF and be able to understand and comply with the requirements of this study

Exclusion Criteria:

Any known allergy to the components or analogues of the investigational product, or those with an allergic constitution (such as allergy to two or more drugs or foods)；

• A history of currently suffering from any other cardiovascular, gastrointestinal, endocrine, hematological, hepatic, immunological, metabolic, urinary, pulmonary, neurological, dermatological, psychiatric, renal and/or other major diseases deemed clinically significant by the investigator;
• Known/confirmed history of malignancy；
• A history of epileptic seizure or increased risk of epileptic seizure, or subjects with a recent history (within six months prior to screening) of head trauma leading to loss of consciousness or concussion;
• A history of currently suffering from hypothalamic dysfunction;
• Significant acute/chronic infections within two weeks prior to dosing;
• Undergone major surgical procedures (such as coronary artery bypass grafting, organ resection, gynecological surgery, etc.) within six months prior to screening or plan to undergo any surgery during the trial;
• Participated in other clinical trials (except those who have not received any intervention) within 3 months prior to dosing, Or are participating in other clinical trials.
• Have lost or donated more than 400 mL of blood within 3 months prior to screening;
• Have taken any prescription/over-the-counter drugs or dietary supplements ,within 7 days prior to dosing or within 5 half-lives of the drug (whichever is longer);
• Clinically significant abnormalities on physical examination or genitourinary ultrasound at the time of screening;
• Clinically significant abnormalities in vital signs, where the criteria for clinically significant blood pressure abnormalities are defined as systolic blood pressure ≥ 140 mmHg or < 90 mmHg, and diastolic blood pressure ≥ 90 mmHg or < 60 mmHg;
• Prolonged QTcF interval in 12-lead ECG results (> 450 ms for males, > 470 ms for females) or clinically significant abnormalities in other 12-lead ECG parameters at screening;
• Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyltransferase (GGT), total bilirubin (TBIL), blood creatinine (CRE), blood urea nitrogen (BUN), or international normalized ratio (INR) higher than the upper limit of normal (ULN) at screening, that are considered as clinically significant abnormalities by the investigator;
• Part 3 only: abnormal sex hormone levels at screening that are considered clinically significant by the investigator;
• Clinically significant abnormalities in thyroid function, parathyroid function, and neck ultrasound results at screening;
• Women with positive pregnancy test result or those who are breastfeeding before dosing;
• Positive hepatitis C virus antibody (HCV Ab), positive human immunodeficiency virus antibody (HIV Ab) or positive hepatitis B surface antigen (HbsAg) result at screening;
• Unable to refrain from consuming grapefruit, pomelo, grapefruit juice, or pomelo juice from 7 days prior to dosing until the end of the study;
• Unable to refrain from consuming any foods or beverages containing caffeine or xanthine (such as coffee, strong tea, chocolate, etc.) from 7 days prior to dosing until the end of the study;
• Unable to abstain from smoking/using tobacco products from 7 days prior to dosing until the end of the study, or positive urine cotinine test result before dosing
• Unable to refrain from consuming alcohol from 7 days prior to dosing until the end of the study, or positive breath alcohol test result before dosing;
• Any history of narcotic use or drug abuse, or positive urine drug screening result before dosing;
• Any medical or other condition, in the opinion of the investigator, may affect the clinical trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: GS1-144 tablet	Drug: GS1-144 tablet; GS1-144 tablet is an NK3R antagonist.
Placebo Comparator: placebo controlled study	Drug: GS1-144 tablet; GS1-144 tablet is an NK3R antagonist.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Part 1:Number of Participants With Treatment -Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)	Number of participants with TEAEs and SAEs will be reported	Up to Day 4
Part 2: Number of Participants With Treatment -Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs).	Number of participants with TEAEs and SAEs will be reported.	Up to Day 9;
Part 3: Number of Participants With TEAEs and SAEs	Number of female post-menopausal participants with TEAEs and SAEs will be reported.	Up to Day 12

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Part1,Part2 and Part3 AUC0-t- Area Under the Drug Concentration-time Curve From Time 0 to the Last Sample Collection Time t for GS1-144	AUC0-t will be assessed and reported.	Part 1 Day 1- pre-dose and up to 72 hour post-dose; Part 2 Days 1 and 6-pre-dose and up to 72 hour post-dose, Part 3 Days 1 and 7-pre-dose and up to 72 hour post-dose,
Part 1 , Part2 and Part 3: AUC0-infinity- Area Under the Drug Concentration-time Curve From 0 to Infinity for GS1-144	AUC0-infinity will be assessed and reported.	Part 1 Day 1- pre-dose and up to 72 hour post-dose; Part 2 Days 1 and 6-pre-dose and up to 72 hour post-dose, Part 3 Days 1 and 7-pre-dose and up to 72 hour post-dose,
Part 1, Part2 and Part 3: Cmax- Maximum Observed Plasma Concentration for GS1-144	Cmax will be assessed and reported.	Part 1 Day 1- pre-dose and up to 72 hour post-dose; Part 2 Days 1 and 6-pre-dose and up to 72 hour post-dose, Part 3 Days 1 and 7-pre-dose and up to 72 hour post-dose,
Part 1 Part2 and Part 3: Tmax- Time to Reach the Maximum Plasma Concentration (Cmax) for GS1-144	Tmax will be assessed and reported.	Part 1 Day 1- pre-dose and up to 24 hour post-dose; Part 2 Days 1 and 7-pre-dose and up to 30 hour post-dose
Part 1 Part2 and Part 3:: T1/2- Terminal Half-life for GS1-144	T1/2 will be assessed and reported.	Time Frame: Part 1 Day 1- pre-dose and up to 72 hour post-dose; Part 2 Days 1 and 6-pre-dose and up to 72 hour post-dose, Part 3 Days 1 and 7-pre-dose and up to 72 hour post-dose
Part 1 Part2 and Part 3: CL/F- Apparent Clearance for GS1-144	CL/F will be assessed and reported.	Part 1 Day 1- pre-dose and up to 72 hour post-dose; Part 2 Days 1 and 6-pre-dose and up to 72 hour post-dose, Part 3 Days 1 and 7-pre-dose and up to 72 hour post-dose
Part 1 Part2 and Part 3: Vd/F- Apparent Volume of Distribution for GS1-144	Vd/F will be assessed and reported.	Part 1 Day 1- pre-dose and up to 72 hour post-dose; Part 2 Days 1 and 6-pre-dose and up to 72 hour post-dose, Part 3 Days 1 and 7-pre-dose and up to 72 hour post-dose
Cmax,ss- Observed Maximum Concentration at Steady State for GS1-144	Cmax at steady state will be assessed and reported.	Part 3 Days 1 and 7-pre-dose and up to 72 hour post-dose
Part 3: Cmin,ss- Observed Minimum Concentration at Steady State for GS1-144	Cmin at steady state will be assessed and reported.	Part 3 Days 1 and 7-pre-dose and up to 72 hour post-dose
Part 3: Tmax,ss- Time of Cmax at Steady State for GS1-144	Tmax at steady state will be assessed and reported.	Part 3 Days 1 and 7-pre-dose and up to 72 hour post-dose
Part 3: Cavg,ss- Average Concentration at Steady State for GS1-144	Cavg at steady state will be assessed and reported.	Part 3 Days 1 and 7-pre-dose and up to 72 hour post-dose
Part 3: AUC0-τ- Area Under the Drug Concentration-time Curve During the Dosing Interval at Steady State for GS1-144	AUC0-T at steady state will be assessed and reported.	Part 3 Days 1 and 7-pre-dose and up to 72 hour post-dose
Part 3: CLss/F- CL for Bioavailability at Steady State for GS1-144	CL/F at steady state will be assessed and reported.	Part 3 Days 1 and 7-pre-dose and up to 30 hour post-dose
Part 3: T1/2,ss- Terminal Half-life at Steady State for GS1-144	T1/2 at steady state will be assessed and reported.	Part 3 Days 1 and 7-pre-dose and up to 72 hour post-dose
Part 3: Accumulation Ratio for GS1-144	Accumulation Ratio will be assessed and reported.	Part 3 Days 1 and 7-pre-dose and up to 72 hour post-dose
Part 1: Baseline and placebo-adjusted changes in ∆∆QTc and other ECG parameters after oral administration of GF1-144 in healthy subjects		Part 1 Day 1- pre-dose and up to 24 hour post-dose

Collaborators and Investigators

• Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): January 3, 2024
• Primary Completion (Actual): January 6, 2024
• Study Completion (Actual): November 5, 2024

Study Registration Dates

• First Submitted: April 11, 2024
• First Submitted That Met QC Criteria: April 23, 2024
• First Posted (Actual): April 25, 2024

Study Record Updates

• Last Update Posted (Actual): May 8, 2025
• Last Update Submitted That Met QC Criteria: May 7, 2025
• Last Verified: May 1, 2025

More Information

Terms related to this study

• Other Study ID Numbers: GenSci074-101

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No